Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by andoon Jan 27, 2019 5:52pm
81 Views
Post# 29287226

RE:RE:RE:RE:just confirmed

RE:RE:RE:RE:just confirmedI use Stockwatch. Under trade workstation all kinds of good data. House Positions for C:ACST from 20190125 to 20190125 House Bought $Val Ave Sold $Val Ave Net $Net 2 RBC 124,800 174,931 1.402 2,458 3,255 1.324 122,342 -171,676 43 Caldwell 19,300 26,153 1.355 0 19,300 -26,153 36 Latimer 200 271 1.355 327 462 1.413 -127 191 13 Instinet 2,100 2,788 1.328 2,700 3,689 1.366 -600 901 19 Desjardins 0 1,000 1,320 1.32 -1,000 1,320 88 Credential 3,500 4,725 1.35 5,000 6,800 1.36 -1,500 2,075 7 TD Sec 962 1,279 1.33 6,220 8,518 1.369 -5,258 7,239 85 Scotia 0 8,512 11,351 1.334 -8,512 11,351 83 Mackie 0 10,000 13,900 1.39 -10,000 13,900 99 Jitney 0 21,000 30,450 1.45 -21,000 30,450 1 Anonymous 42,190 58,331 1.383 80,112 110,271 1.376 -37,922 51,940 79 CIBC 14,327 19,444 1.357 70,050 97,906 1.398 -55,723 78,462 TOTAL 207,379 287,922 1.388 207,379
Bullboard Posts